NCT04158362
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Endocrine (Hormone) Therapy, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with bone-only metastasis; Patients with symptomatic progressive brain metastasis that require treatment – see trial for details; Patients who have received 1 line of endocrine therapy and/or chemotherapy for metastatic disease
https://ClinicalTrials.gov/show/NCT04158362